Journal of Clinical Endocrinology & Metabolism, Vol 75, 1310-1317, Copyright © 1992 by Endocrine Society

ARTICLES

Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro

TW de Bruin, DJ Kwekkeboom, JW Van't Verlaat, JC Reubi, EP Krenning, SW Lamberts and RJ Croughs
Department of Medicine, Utrecht Academic Hospital, The Netherlands.

We have studied seven patients with a clinically nonfunctioning or alpha-subunit-secreting pituitary macroadenoma, four of whom received long term, high dose octreotide treatment. We have attempted to correlate the presence of somatostatin receptors (SS-R) in the adenomas and the outcome of octreotide treatment, as measured by tumor size, improvements in visual field defects, and hormonal response. The presence of SS-R in the pituitary adenomas was demonstrated in vivo using [111indium]octreotide scintigraphy and in vitro by autoradiography of tissue fragments obtained after transsphenoidal surgery. Adenomas from six of the seven subjects were SS-R positive. High dose (1200 micrograms, sc, daily) octreotide treatment was given to four subjects, three of whom were SS-R positive. Improvement of the visual field defects was observed in three of four patients (including the SS-R-negative subject), although no computed tomographic scan- assessed tumor size reduction was found. Two of four patients showed small but significant reductions in serum FSH concentrations (to 83% and 93% of initial values) with treatment. These in vivo responses to high dose octreotide treatment could not be predicted by pretreatment responses to 200 micrograms TRH or 100 micrograms octreotide. Tissue fragments for cell culture were obtained from six patients, and in vitro release of gonadotropins and/or alpha-subunit could be demonstrated in five cultures. In vitro, octreotide (10 nmol/L) significantly decreased gonadotropiin or subunit release in three of five cultures, whereas bromocriptine (10 nmol/L) significantly reduced the release in four of five cultures and to a significantly greater extent than octreotide. In conclusion, in six of seven patients with a clinically nonfunctioning or alpha-subunit-secreting pituitary adenoma, SS-R were demonstrated in the tumor. In vitro incubation of adenoma cells with octreotide resulted in mild inhibition of gonadotropin or alpha-subunit release. Although in vivo long term treatment with high doses of octreotide did not result in substantial tumor size reduction, improvement of visual field defects was observed in three of four subjects.

This article has been cited by other articles:

				O. M. Dekkers, A. M. Pereira, and J. A. Romijn Treatment and Follow-Up of Clinically Nonfunctioning Pituitary Macroadenomas J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3717 - 3726. [Abstract] [Full Text] [PDF]

				T. Florio, F. Barbieri, R. Spaziante, G. Zona, L. J Hofland, P. M van Koetsveld, R. A Feelders, G. K Stalla, M. Theodoropoulou, M. D Culler, et al. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study Endocr. Relat. Cancer, June 1, 2008; 15(2): 583 - 596. [Abstract] [Full Text] [PDF]

				A. Colao, M. Filippella, R. Pivonello, C. Di Somma, A. Faggiano, and G. Lombardi Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S57 - S63. [Abstract] [Full Text] [PDF]

				G. F Taboada, R. M Luque, W. Bastos, R. F C Guimaraes, J. B Marcondes, L. M C Chimelli, R. Fontes, P. J P Mata, P. N. Filho, D. P Carvalho, et al. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas Eur. J. Endocrinol., January 1, 2007; 156(1): 65 - 74. [Abstract] [Full Text] [PDF]

				E. Ferrante, M. Ferraroni, T. Castrignano, L. Menicatti, M. Anagni, G. Reimondo, P. Del Monte, D. Bernasconi, P. Loli, M. Faustini-Fustini, et al. Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors Eur. J. Endocrinol., December 1, 2006; 155(6): 823 - 829. [Abstract] [Full Text] [PDF]

				W. W de Herder, A. E M Reijs, R. A Feelders, M. O van Aken, E. P Krenning, H. L J Tanghe, A.-J. van der Lely, and D. J Kwekkeboom Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging? Eur. J. Endocrinol., November 1, 2006; 155(5): 717 - 723. [Abstract] [Full Text] [PDF]

				L. J. Hofland and S. W. J. Lamberts The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance Endocr. Rev., February 1, 2003; 24(1): 28 - 47. [Abstract] [Full Text] [PDF]

				D. Kwekkeboom, E. P. Krenning, and M. de Jong Peptide Receptor Imaging and Therapy J. Nucl. Med., October 1, 2000; 41(10): 1704 - 1713. [Abstract] [Full Text] [PDF]

				D. Ferone, S. Lastoria, A. Colao, P. Varrella, G. Cerbone, W. Acampa, B. Merola, M. Salvatore, and G. Lombardi Correlation of Scintigraphic Results Using 123I-Methoxybenzamide with Hormone Levels and Tumor Size Response to Quinagolide in Patients with Pituitary Adenomas J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 248 - 252. [Abstract] [Full Text]

				S. J. Hurel, P. E. Harris, A. M. McNicol, S. Foster, W. F. Kelly, and P. H. Baylis Metastatic Prolactinoma: Effect of Octreotide, Cabergoline, Carboplatin and Etoposide; Immunocytochemical Analysis of Proto-Oncogene Expression J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2962 - 2965. [Abstract] [Full Text] [PDF]

				L. J. Hofland, W. W. de Herder, H. A. Visser-Wisselaar, C. van Uffelen, M. Waaijers, J. Zuyderwijk, P. Uitterlinden, M. J. M. Kros, P. M. van Koetsveld, and S. W. J. Lamberts Dissociation between the Effects of Somatostatin (SS) and Octapeptide SS-Analogs on Hormone Release in a Small Subgroup of Pituitary- and Islet Cell Tumors J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 3011 - 3018. [Abstract] [Full Text] [PDF]

				S. W.J. Lamberts, A.-J. van der Lely, W. W. de Herder, and L. J. Hofland Octreotide N. Engl. J. Med., January 25, 1996; 334(4): 246 - 254. [Full Text] [PDF]